CompaniesOdonate Therapeutics

Odonate Therapeutics

defunct

About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (4)

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

1,224

By Phase

PHASE1: 1PHASE2: 2PHASE3: 1

By Status

TERMINATED: 4

Clinical Trials Pipeline4 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2016

2017

2018

2019

2020

2021

2022

Today

Hover over trial bars to see details

Recent Trials

NCT04312282Lead Sponsor

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

PHASE1Terminated

93 participants

Started: Mar 6, 2020 · Completed: Jun 15, 2021

NCT03952325Lead Sponsor

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

PHASE2Terminated

294 participants

Started: Jul 9, 2019 · Completed: Jun 23, 2021

NCT03858972Lead Sponsor

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

PHASE2Terminated

152 participants

Started: Feb 5, 2019 · Completed: Jun 11, 2021

NCT03326674Lead Sponsor

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

PHASE3Terminated

685 participants

Started: Dec 21, 2017 · Completed: Jun 28, 2021

Funding History (20)

8-K

Jan 7, 2022

8-K

Nov 18, 2021

8-K

Aug 5, 2021

8-K

Jun 25, 2021

DEF 14A

Jun 1, 2021

8-K

Mar 25, 2021

8-K

Feb 23, 2021

8-K

Dec 15, 2020

8-K

Dec 15, 2020

8-K

Dec 14, 2020